Physician profile
Rosa Pacheco
NPI 1306836234
$3,061.54
in general payments reported to CMS, 2019-2025
31 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $62.09 · 2021: $26.21 · 2022: $758 · 2023: $742 · 2024: $834 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $390.30 | 2022-2025 | |
| Exact Sciences Corporation | $382.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.36 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $320.93 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $199.84 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $168.96 | 2021-2024 | |
| Glaxosmithkline, LLC. | $152.99 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $128.76 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $93.95 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $72.51 | 2022-2023 | |
| Pfizer INC. | $63.41 | 2022-2025 | |
| Watermark Medical, INC. | $62.09 | 2020 | |
| Ibsa Pharma INC. | $61.66 | 2023 | Tirosint, Licart |
| Janssen Pharmaceuticals, INC | $61.49 | 2023-2024 | Spravato, Xarelto |
| Amgen INC. | $59.21 | 2022-2025 | Otezla, Repatha, Prolia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $58.66 | 2022-2024 | |
| Amarin Pharma, INC. | $52.98 | 2022-2023 | |
| Agios Pharmaceuticals, INC. | $46.70 | 2025 | Pyrukynd |
| Merck Sharp & Dohme LLC | $43.53 | 2022 | |
| Xeris Pharmaceuticals, INC. | $43.45 | 2022 | |
| Antares Pharma, INC. | $40.76 | 2022 | |
| Daiichi Sankyo INC. | $32.78 | 2022-2023 | Injectafer |
| Idorsia Pharmaceuticals US INC | $31.94 | 2022-2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.50 | 2022 | |
| Corcept Therapeutics | $23.74 | 2025 | Korlym |
| Pentax of America, INC. | $22.90 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon |
| Medtronic, INC. | $20.50 | 2024 | Intellis Adaptivestim |
| Amneal Pharmaceuticals LLC | $18.01 | 2023 | Unithroid |
| Lundbeck LLC | $16.55 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $13.83 | 2023 | |
| Bausch Health US, LLC | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Pacheco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.